Myriad Genetics, Inc. (MYGN) said it now projects, fiscal 2020 adjusted earnings per share in a range of $1.00-$1.10; and revenue of $800-810 million. The company has revised its revenue accrual rate, and is forecasting lower hereditary cancer rates for fiscal 2020. Analysts polled by Thomson Reuters expect the company to report profit per share of $1.82, on revenue of $872.35 million. Analysts' estimates typically exclude special items.
from RTT - Earnings https://ift.tt/34tqFL7
via IFTTT
No comments:
Post a Comment